However, although highly potent BCL-XL inhibitors such as ABT-737, ABT-263, A1331852 and others are available, one major impediment to their clinical use is the on-target and dose-limiting thrombocytopenia that these inhibitors cause in patients [23, 58]. The gene discussed is BCL2L1; the disease is Thrombocytopenia.